![FTD Respiratory Pathogens 21 Assay](https://marketing.webassets.siemens-healthineers.com/2c43c6d016f7bcef/a4e0d1535431/v/79242f5bbf65/ftd-respiratory-pathogens-21-assay.jpg)
FTD Respiratory Pathogens 21 Assay
Syndromic testing for upper respiratory infections using multiplex RT-PCR
The FTD™ Respiratory pathogens 21 assay1 is a qualitative in vitro nucleic acid amplification test for the detection and differentiation of specific viral and bacterial nucleic acids in nasopharyngeal swab specimens of human origin.
The test is intended as an aid in the diagnosis of respiratory infections caused by influenza A virus (IAV), influenza A virus H1N1 swine-lineage (IAV [H1N1] swl), influenza B virus (IBV), human rhinovirus (HRV), human coronaviruses (HCoV) 229E, NL63, HKU1, and OC43, human parainfluenza viruses (HPIV) 1 through 4, human metapneumoviruses (HMPV) A and B, human bocavirus (HBoV), Mycoplasma pneumoniae (M. pneumoniae), human respiratory syncytial viruses (HRSV) A and B, human parechovirus (HPeV), enterovirus (EV), and human adenovirus (HAdV).
Ця інформація вам допомогла?
CE-marked for in vitro diagnostic use in the EU.
WHO, 2023
CDC, 2023
Ramanan et al., Syndromic Panel-Based Testing in Clinical Microbiology, CMR, 2018.